Press Room

AAPS 2023 PharmSci 360

Start
Sunday, October 22, 2023
End
Wednesday, October 25, 2023
Location: Orlando, USA
Booth Number: 2429

 

Visit Hovione’s booth at AAPS PharmSci 360 next October 22-23 in Orlando and meet our team of experts.

The AAPS PharmSci 360 Annual Meeting is organized by the American Association of Pharmaceutical Scientists (AAPS). The event provides a platform for pharmaceutical scientists from academia, industry, government, and other institutions worldwide to exchange knowledge and discuss the latest advancements in the field.

Schedule a meeting with our experts to learn how our end-to-end solutions in one site can support your projects.

Our experts traveling to Orlando will present the following posters:

 

HOVIONE POSTERS

 

Monday, October 23, 2023

Manufacturing and Analytical Characterization – Chemical
Impact of Alternative Lubricants on Tablet Parameters Approaching the Over-Lubrication Problems in Continuous Direct Compression Processes

  • 1:30 PM – 2:30 PM ET
  • Presenting: Nuno Branco, Ph.D.
  • Main Author: Tomas Santos, B.S.
     

Formulation and Delivery – Biomolecular
Hot and Cold Formulation of Biologics for the Optimization of Drying Technologies

  • 3:30 PM – 4:30 PM ET
  • Presenting: Paulo Lino, Ph.D.
  • Main Author: Susana Farinha, M.Sc.
     

Tuesday, October 24, 2023

Formulation and Delivery – Biomolecular
Analytical Characterization for Nucleic Acid Therapy: A Case Study

  • 12:30 PM – 1:30 PM ET
  • Main Author; Presenting: Rute Mota, M.Sc.
     

Formulation and Delivery – Chemical
Beyond Conventional Boundaries: New Excipients for ASD Formulation

  • 2:30 PM – 3:30 PM ET
  • Presenting; Main Author: Francisco Tavares, M.Sc.

 

Wednesday, October 25, 2023

Formulation and Delivery – Chemical
Dispersome® a Viable Alternative toward Enhanced Drug Load and Bioavailability

  • 9:30 AM – 10:30 AM ET
  • Presenting: Francisco Tavares, M.Sc.
  • Main Author: Maria Paisana, Ph.D.
     

Manufacturing and Analytical Characterization – Chemical
Challenges in Nitrosamine Determination for Pharmaceutical Products: An Analytical Perspective

  • 10:30 AM – 11:30 AM ET
  • Presenting; Main Author: Marco Galésio, Ph.D.
     

EXTRA PRESENTATION - Special Poster Collection

 

Tuesday, October 24, 2023 2:30 PM – 3:30 PM ET 

Location: Poster Forum #7; Exhibit Hall West A4-B3

 

Manufacturing and Analytical Characterization – Chemical
Impact of Alternative Lubricants on Tablet Parameters Approaching the Over-Lubrication Problems in Continuous Direct Compression Processes

  • Presenting: Nuno Branco, Ph.D.
  • Main Author: Tomas Santos, B.S.
     

Don’t miss the chance to speak with our team. Visit us at Booth #2429.
See you in Orlando.
 

 

Let’s discuss your project together.

schedule a meeting

 

 

 

Schedule a meeting with our experts.

 

Find more about AAPS PharmSci 360.

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024